Aveanna Healthcare Holdings Inc. Form 8-K Summary
Business Context and Reporting Period
Aveanna Healthcare Holdings Inc. filed a current report on May 13, 2021, reporting a change to its board of directors. The report was signed on May 19, 2021. Aveanna’s common stock trades on Nasdaq under the symbol AVAH.
Board Appointment and Governance
- The board expanded Class III from three to four directors.
- Erica Schwartz, M.D., J.D., M.P.H., was appointed to fill the resulting vacancy.
- Dr. Schwartz will serve until the 2024 Annual Meeting of Stockholders, unless her service ends earlier under applicable circumstances.
- She is expected to serve on the Clinical Quality and Compliance Committee.
- The board determined that Dr. Schwartz is independent under SEC and Nasdaq rules.
- The filing states that there are no arrangements or understandings related to her appointment and no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K.
- Dr. Schwartz will receive the standard compensation applicable to non-employee directors, as described in Aveanna’s April 28, 2021 prospectus.
Financial Metrics and Material Changes
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating and financial metrics. It does not report a material change to the company’s financial results or outlook.
Management Commentary, Risks, and Unusual Items
Dr. Schwartz previously served as Deputy Surgeon General at the U.S. Department of Health and Human Services and led the U.S. public health deployment in response to the COVID-19 pandemic. The filing does not identify specific risks, contingencies, unusual charges, or changes to business guidance.
Key Facts for Investors to Verify
- Confirm Dr. Schwartz’s appointment, independence status, and expected committee assignment.
- Review the company’s subsequent filings for any changes to board composition or committee assignments.
- Review separate earnings releases and periodic reports for Aveanna’s financial performance, debt, liquidity, and outlook, which are not included in this 8-K.
- Review the April 28, 2021 prospectus for the applicable non-employee director compensation arrangements.